Tag: cell therapy

September 9, 2021

Obsidian Therapeutics has raked in $115 million to realize the long-unfulfilled therapeutic promise of tumor-infiltrating lymphocytes (TILs). The series B gives Obsidian a shot at showing whether freeing TILs from IL-2 can finally unleash power that research has hinted at […]

September 8, 2021

The deal with see Adaptimmune receive $150m upfront, another $150m over the next five years and then milestone payments potentially exceeding $3bn in aggregate sales, as well as royalties. Unlike other leaders in next-generation cell therapies, the partners will use […]

August 25, 2021

CAR-T cell therapies, which involve engineering a patient’s own T cells to target and kill cancer cells bearing specific antigens, has shown strong results in blood disorders. But many patients still progress or relapse after initial remission, because tumor cells […]

August 24, 2021

Recent interest in gene therapies and the genetic constructs on which they are based is causing a flurry of activity in facility construction and expansion. After they are manufactured doses must be stored, shipped, and stored again as they await […]

August 19, 2021

The amount of money flowing into cell and gene therapy development suggests investor confidence in the field’s future remains high, even as clinical, regulatory and commercial setbacks have hindered a number of companies, such as Bluebird bio, Biogen and Adverum […]

August 17, 2021

Innoforce Pharmaceuticals has opened a new advanced cell and gene therapy development facility in Hangzhou, China. Analytical development (AD) and process development (PD) represents a critical step towards providing services for potential clients in their cell and gene therapy product […]

August 13, 2021

On Aug 12, 2021, Lykan Bioscience, a US-based contract development and manufacturing organization (CDMO) focused on cell-based therapies, and Vineti, a US-based enterprise software platform company, announced a partnership that will combine Lykan’s purpose-built, multi-product cell therapy manufacturing facility located […]

August 11, 2021

New market research states the global cell and gene therapy manufacturing services market will reach $13.8 billion by 2026, expanding at a compound annual growth rate (CAGR) of 12.4 percent from its current value of $7.7 billion (in 2021). The […]

August 6, 2021

The reasons behind this problem, however, are rarely studied or understood. Despite this, new strategies devised over the last five years are beginning to reverse the trend, and both reduce stigma and increase awareness to funnel new patients into these […]

August 2, 2021

Investors have flocked to T-knife Therapeutics, which has been taking aim at solid tumors, an area where cell therapies have struggled to perform as well as they have in some blood cancers. Just last year, the biotech raised €66 million […]

July 28, 2021

A compassionate-use study has generated promising results for the potential treatment of muscular dystrophies using mesenchymal stem cells (MSCs) derived from Wharton’s jelly (WJ), a substance found in the umbilical cord. The study, led by doctors at Klara Medical Center […]

July 20, 2021

BlueRock – a Bayer subsidiary – is currently evaluating the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study. This early-stage trial is set to enrol ten patients across the US and Canada, with its primary objective to […]